Kuros Biosciences (SWX:KURN) raised its full year 2026 earnings guidance, telling investors it now targets sales growth between 36% and 40%, a shift that puts updated expectations center stage.
The guidance upgrade lands after a sharp 24.63% 7 day share price return and a 19.25% 30 day share price return, yet the stock is still down 21.29% on a year to date share price basis and the 1 year total shareholder return has declined 28.03%, while very large 3 and 5 year total shareholder returns suggest long term holders have already seen substantial gains and newer buyers are pricing in fresh expectations around Kuros Biosciences.
Compare Kuros Biosciences' upgraded guidance with other growth-driven healthcare plays by scanning the 123 healthcare AI stocks that are already attracting fresh attention from investors.
Kuros Biosciences just reset expectations with faster growth targets and a sharp short term share price rebound. The real question now is whether that story is already fully reflected in the valuation.
Price-to-Earnings of 113.3x: Is it justified?
On simple headline maths, Kuros Biosciences trades on a rich P/E of 113.3x, a level that sits well above many investors' comfort zones when they look at a CHF21 share price.
The P/E ratio compares what the market is willing to pay today for each unit of earnings. For a business like Kuros Biosciences, where management and analysts expect strong earnings growth over the coming years, a high P/E often reflects optimism about future profitability rather than current profits alone.
Analyst forecasts pointing to earnings growth of 65.6% per year and revenue growth of 25.1% per year set some context for this valuation, since the market may be pricing in those projections. Yet the stock is described as expensive compared to its own estimated fair P/E of 53.3x, which suggests the market valuation could shift closer to that level if expectations or sentiment change.
The current 113.3x P/E also looks heavy beside both the peer average of 50.5x and the wider European biotech group on 16.2x. This is a strong gap in both directions and underlines how much more investors are currently paying for each unit of Kuros Biosciences earnings than for sector or peer earnings.
Explore the SWS fair ratio for Kuros Biosciences.
Result: Price-to-Earnings of 113.3x (OVERVALUED)
Still, any stumble in Kuros Biosciences earnings growth or a reset in sector valuations could quickly pressure a P/E multiple that is this far above peers.
Find out about the key risks to this Kuros Biosciences narrative .
Another view on Kuros Biosciences' value
The P/E makes Kuros Biosciences look expensive, yet the SWS DCF model based on projected cash flows points the other way. At CHF21 the shares are described as trading well below an estimated cash flow value of CHF132.46, which frames the current price as deeply discounted on that approach.
Investors weighing up that gap between earnings based pricing and cash flow based value may want to understand how the SWS model treats future growth, capital needs and risk, since those inputs can shift the result sharply over time. Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Kuros Biosciences for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 195 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages on Kuros Biosciences valuation and growth story so far. If that feels unresolved, act promptly and consider both perspectives by reviewing the 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Kuros Biosciences?
If Kuros Biosciences has sharpened your focus on valuation and growth expectations, do not stop here. Use fresh ideas from the Simply Wall Street Screener to keep your shortlist competitive.
-
Target stability first by scanning a 223 resilient stocks with low risk scores that filters for businesses with more resilient profiles and lower risk scores.
-
Hunt for genuine value by reviewing a 195 high quality undervalued stocks that highlights financially strong companies trading below their assessed worth.
-
Spot potential future favourites early by checking a 610 high quality undiscovered gems of high quality stocks that fewer investors are watching today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KURN.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
